Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2025 | Real-world outcomes of first-line avelumab maintenance in bladder cancer

Hiroshi Kitamura • 13 Feb 2025
GU Cancers 2025
Bladder Cancer Genitourinary Cancer Urothelial Carcinoma Antibodies Avelumab

Hiroshi Kitamura, MD, PhD, University of Toyama, Toyama, Japan, discusses findings from the JAVEMACS chart review study, evaluating real-world effectiveness and usage of avelumab first-line maintenance (1LM) in patients with locally advanced or metastatic urothelial carcinoma in Japan. Avelumab 1LM was shown to provide long-term overall survival benefits, regardless of cisplatin eligibility. This interview took place at the ASCO GU Cancers Symposium 2025 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Hiroshi Kitamura

Managing the common adverse events of avelumab in the clinic
0:50
Managing the common adverse events of avelumab in the clinic
Hiroshi Kitamura • 13 Feb 2025
Comparing avemlumab and EV with pembrolizumab in first line bladder cancer
0:44
Comparing avemlumab and EV with pembrolizumab in first line bladder cancer
Hiroshi Kitamura • 13 Feb 2025

Related Videos

Current and emerging systemic strategies in biochemically relapsed prostate cancer
2:45
Current and emerging systemic strategies in biochemically relapsed prostate cancer
Ashwin Sachdeva • 16 May 2026
How has SABR improved radiotherapy practice in kidney cancer?
1:06
How has SABR improved radiotherapy practice in kidney cancer?
Shankar Siva • 16 May 2026
Which patients with kidney cancer may benefit from SABR treatment?
1:58
Which patients with kidney cancer may benefit from SABR treatment?
Shankar Siva • 16 May 2026
Management of brain metastasis in patients with poor-risk testicular cancer
1:03
Management of brain metastasis in patients with poor-risk testicular cancer
Darren Feldman • 30 May 2026
The content of VJOncology is intended for healthcare professionals